Literature DB >> 6389337

Further evaluation of saline infusion for the diagnosis of primary aldosteronism.

O B Holland, H Brown, L Kuhnert, C Fairchild, M Risk, C E Gomez-Sanchez.   

Abstract

Normal subjects, normal-renin hypertensive patients, and low-renin hypertensive patients were evaluated by intravenous saline infusion and with a fludrocortisone acetate (Florinef) protocol to clarify diagnostic criteria for primary aldosteronism that are recommended for the saline infusion protocol. The patients consumed a 200 mEq sodium, 70 mEq potassium diet for 6 days, and on the last 3 days received Florinef 0.5 mg orally twice daily. On Days 3 and 6, urinary aldosterone and tetrahydroaldosterone excretions were determined, and on Days 4 and 7 plasma aldosterone (PA) was determined at 0600 after overnight recumbency and at 0800 after 2 hours of walking. Although the level of normal PA suppression by saline infusion has been commonly defined as 10 ng/dl, a value of 5 ng/dl was originally recommended. In 20 normal subjects and 45 normal-renin hypertensive patients, we found that the PA was almost always suppressed below 5 ng/dl. In 18 of 75 low-renin patients including five with aldosterone-producing adenoma (APA), the PA was never suppressed below 10 ng/dl; thus, these 18 patients had classical primary aldosteronism by generally accepted criteria. The Florinef protocol was performed in eight of these 18 patients and was abnormal in all. An abnormal Florinef protocol was also found in seven of 15 patients studied with PA suppression after saline infusion to between 5 and 10 ng/dl, but in only one of 24 patients studied with PA suppression below 5 ng/dl. Additional studies in the subgroup with abnormal results from the Florinef protocol indicated that none of these patients had evidence of APA, so they had nontumorous primary aldosteronism (NTPA).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389337     DOI: 10.1161/01.hyp.6.5.717

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  14 in total

1.  A diagnostic algorithm--the holy grail of primary aldosteronism.

Authors:  Gian Paolo Rossi; Teresa Maria Seccia; Achille C Pessina
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 3.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

Review 4.  Primary aldosteronism: diagnostic and therapeutic considerations.

Authors:  Mari K Nishizaka; David A Calhoun
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

5.  MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2.

Authors:  Guoxi Zhang; Xiaofeng Zou; Quanliang Liu; Tianpeng Xie; Ruohui Huang; Huan Kang; Changfu Lai; Jiaxing Zhu
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

Review 6.  Diagnosis and treatment of primary aldosteronism.

Authors:  Gian Paolo D Rossi
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

7.  Surgical treatment of primary hyperaldosteronism.

Authors:  R J Weigel; S A Wells; J C Gunnells; G S Leight
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

Review 8.  Progress in primary aldosteronism: present challenges and perspectives.

Authors:  C E Gomez-Sanchez; G P Rossi; F Fallo; M Mannelli
Journal:  Horm Metab Res       Date:  2010-01-20       Impact factor: 2.936

9.  NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism.

Authors:  Francesca Pizzolo; Francesco Zorzi; Laura Chiecchi; Letizia Consoli; Irene Aprili; Patrizia Guarini; Annalisa Castagna; Gian Luca Salvagno; Chiara Pavan; Oliviero Olivieri
Journal:  Endocrine       Date:  2013-08-13       Impact factor: 3.633

10.  Primary aldosteronism: from case detection to histopathology with up to 6 years of follow-up.

Authors:  Gudbjörg Jonsdottir; Jon Gudmundsson; Gudjon Birgisson; Helga Agusta Sigurjonsdottir
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-11-23       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.